Valiant Labs Reports FY26 Net Profit of ₹554.82 Lakhs; Results Published in Newspapers
Valiant Laboratories published its audited FY26 financial results in Financial Express and Mumbai Lakshadeep on May 16, 2026, per SEBI Regulations 30 and 47. On a standalone basis, the company reported a net profit of ₹554.82 lakhs for FY26 against a net loss of ₹215.02 lakhs in FY25, with revenue rising to ₹21,704.25 lakhs. The consolidated results reflected a net loss of ₹326.79 lakhs for FY26, with revenue from operations at ₹23,746.75 lakhs, as higher subsidiary costs offset a Q4 profit of ₹175.87 lakhs.
*this image is generated using AI for illustrative purposes only.
Valiant Laboratories Limited has published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in newspapers Financial Express (English) and Mumbai Lakshadeep (Marathi) on May 16, 2026, in compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were previously reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 14, 2026, in Mumbai. The intimation has also been uploaded on the company's website at www.valiantlabs.in .
Standalone Financial Performance
On a standalone basis, the company delivered a strong turnaround in FY26, swinging to a net profit of ₹554.82 lakhs compared to a net loss of ₹215.02 lakhs in the previous year. Revenue from operations rose significantly to ₹21,704.25 lakhs from ₹13,336.18 lakhs in FY25. For the quarter ended March 31, 2026, the standalone net profit stood at ₹353.28 lakhs on total income of ₹6,607.61 lakhs. The standalone results reflect a pre-tax profit of ₹754.79 lakhs for FY26, compared to a pre-tax loss of ₹144.78 lakhs in FY25.
| Metric | Q4 FY26 (₹ Lakhs) | FY26 (₹ Lakhs) | Q4 FY25 (₹ Lakhs) | FY25 (₹ Lakhs) |
|---|---|---|---|---|
| Revenue from Operations | 6,530.34 | 21,704.25 | 5,777.00 | 13,336.18 |
| Total Income | 6,607.61 | 21,993.73 | 5,842.39 | 13,878.99 |
| Net Profit/(Loss) before Tax | 473.49 | 754.79 | 392.36 | (144.78) |
| Net Profit/(Loss) after Tax | 353.28 | 554.82 | 323.83 | (215.02) |
| Total Comprehensive Income | 352.03 | 554.39 | 321.56 | (217.28) |
| Basic EPS (₹) | 0.65 | 1.02 | 0.74 | (0.50) |
| Diluted EPS (₹) | 0.70 | 1.10 | 0.74 | (0.50) |
Consolidated Financial Performance
On a consolidated basis, which includes subsidiary Valiant Advanced Sciences Private Limited, the group reported a net loss of ₹326.79 lakhs for FY26. Revenue from operations for the year increased to ₹23,746.75 lakhs. The consolidated results reflect higher costs associated with the subsidiary's operations, resulting in a net loss for the full year despite a profit of ₹175.87 lakhs in Q4 FY26. The consolidated pre-tax profit for the quarter stood at ₹104.68 lakhs.
| Metric | Q4 FY26 (₹ Lakhs) | FY26 (₹ Lakhs) | Q4 FY25 (₹ Lakhs) | FY25 (₹ Lakhs) |
|---|---|---|---|---|
| Revenue from Operations | 9,198.18 | 23,746.75 | 5,778.56 | 13,338.20 |
| Total Income | 9,215.30 | 23,978.79 | 5,547.10 | 13,881.68 |
| Net Profit/(Loss) before Tax | 104.68 | 76.82 | 93.91 | (151.26) |
| Net Profit/(Loss) after Tax | 175.87 | (326.79) | 70.36 | (220.12) |
| Total Comprehensive Income | 176.07 | (326.37) | 67.96 | (222.52) |
| Basic EPS (₹) | 0.32 | (0.51) | 0.16 | (0.51) |
| Diluted EPS (₹) | 0.35 | (0.51) | 0.16 | (0.51) |
Additional Financial Details
The paid-up equity share capital stood at ₹5,431.25 lakhs as of March 31, 2026, compared to ₹4,345.00 lakhs in the previous year, on both standalone and consolidated basis. Reserves excluding revaluation reserves as per the balance sheet stood at ₹26,544.62 lakhs (standalone) and ₹25,657.26 lakhs (consolidated) for FY26, against ₹19,093.31 lakhs and ₹19,086.01 lakhs respectively in FY25. The financial results have been prepared in accordance with Indian Accounting Standards (IndAS) as prescribed under Section 133 of the Companies Act, 2013, and are available on the BSE, NSE, and the company's website. The full format of the financial results is accessible at www.bseindia.com , www.nseindia.com , and www.valiantlabs.in .
Historical Stock Returns for Valiant Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.84% | -5.28% | -4.16% | +11.13% | -30.87% | -56.19% |
Can Valiant Advanced Sciences Private Limited achieve operational breakeven in FY27, and what strategic steps is management taking to reduce the subsidiary's drag on consolidated profitability?
With equity share capital increasing from ₹4,345 lakhs to ₹5,431.25 lakhs, how will Valiant Laboratories deploy the capital raised and what revenue growth targets has management set for FY27?
Given the nearly 63% year-on-year surge in standalone revenue, how sustainable is this growth trajectory, and which product segments or geographies are driving the expansion?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
